AUROPHARMA:NSE:NSE-Aurobindo Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1466.05

Change

+7.45 (+0.51)%

Market Cap

USD 851.48B

Volume

0.92M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India. Address: Galaxy, Plot No. 1, Hyderabad, India, 500032

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-0.80 (-0.04%)

USD 4,554.89B
DIVISLAB:NSE Divi's Laboratories Limited

-4.75 (-0.09%)

USD 1,441.57B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+81.40 (+2.40%)

USD 1,154.88B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-102.40 (-1.52%)

USD 1,121.95B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-11.70 (-1.09%)

USD 1,071.49B
MANKIND:NSE Mankind Pharma Ltd

+73.85 (+2.91%)

USD 1,033.59B
LUPIN:NSE Lupin Limited

+14.65 (+0.67%)

USD 998.11B
ALKEM:NSE Alkem Laboratories Limited

+34.85 (+0.57%)

USD 740.60B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

+18.35 (+1.12%)

USD 473.60B
AJANTPHARM:NSE Ajanta Pharma Limited

-26.20 (-0.78%)

USD 418.19B

ETFs Containing AUROPHARMA:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.73% 58% F 68% D+
Dividend Return 0.14% 8% B- 9% A-
Total Return 35.87% 59% D- 67% D+
Trailing 12 Months  
Capital Gain 62.74% 63% D 70% C-
Dividend Return 0.50% 44% F 38% F
Total Return 63.24% 64% D 70% C-
Trailing 5 Years  
Capital Gain 158.33% 27% F 37% F
Dividend Return 3.83% 35% F 27% F
Total Return 162.17% 27% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain 30.34% N/A N/A 43% F
Dividend Return 31.07% N/A N/A 43% F
Total Return 0.74% N/A N/A 54% F
Risk Return Profile  
Volatility (Standard Deviation) 59.85% N/A N/A 39% F
Risk Adjusted Return 51.92% N/A N/A 29% F
Market Capitalization 851.48B 91% A- 94% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector